These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29069705)

  • 1. [The Impact of Multiple Intravitreal Anti-VEGF Injections on Intraocular Pressure].
    Lamprakis I; Todorova MG; Grüb M; Schlote T
    Klin Monbl Augenheilkd; 2018 Nov; 235(11):1278-1284. PubMed ID: 29069705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
    Good TJ; Kimura AE; Mandava N; Kahook MY
    Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
    Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
    JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
    J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
    Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
    Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
    Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
    Adelman RA; Zheng Q; Mayer HR
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
    Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
    Demirel S; Yanik O; Batioglu F; Ozmert E
    Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
    Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
    Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.